title: Efficacy of octreotide in the control of acute upper gastrointestinal bleeding.
abstract: To evaluate the efficacy and safety of octreotide in the control of acute upper gastrointestinal (GI) bleeding and prevention of rebleeding, the Gastroenterology Unit, Chulalongkorn University Hospital, conducted a prospective open study in patients with acute upper GI bleeding. All patients with acute upper GI bleeding were given octreotide by intravenous infusion. The patients then had endoscopic confirmation within 24 hours, were divided into variceal and nonvariceal groups, and then randomly allocated to receive either 48 hours of octreotide infusion or 48 hours of octreotide infusion plus 72 hours subcutaneous injection. Efficacy and safety of octreotide were evaluated during the 5 days observation period. Forty-three patients with acute upper GI bleeding were treated with octreotide infusion. After endoscopy, 16 patients in the variceal group and 22 patients in the non-variceal group were randomized to receive 48 hours infusion or 48 hours infusion plus 72 hours subcutaneous infusion. Failure to control active bleeding occurred in 11 patients (28.9%) and failure to prevent rebleeding was found in 5 patients (13.2%). The results showed that the effect of octreotide infusion in controlling acute upper GI bleeding appeared to be not different between the variceal and non-variceal causes. Subcutaneous injection of octreotide for another 72 hours showed no apparent benefit for the prevention of rebleeding.
authors: Department of Medicine, Faculty of Medicine, Chulalongkom University, Bangkok, Thailand.
authors: P
authors: P
authors: Kullavanuaya
authors: S
authors: S
authors: Manotaya
authors: D
authors: D
authors: Thong-Ngam
authors: V
authors: V
authors: Mahachai
authors: N
authors: N
authors: Kladchareon
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000517:prevention & control*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D011446:Prospective Studies; D055502:Secondary Prevention
chemical_list: D006490:Hemostatics; D015282:Octreotide